88 research outputs found
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and
well tolerated in the phase 3 TELESTAR study in patients with carcinoid
syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on
somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the
safety and efficacy of telotristat ethyl in patients with CS (diarrhea,
flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic
acid (u5-HIAA)) with <4 BMs/day on SSAs (or ≥1 symptom or ≥4 BMs/day if not on
SSAs) during a 12-week double-blind treatment period followed by a 36-week
open-label extension (OLE). The primary safety and efficacy endpoints were
incidence of treatment-emergent adverse events (TEAEs) and percent change from
baseline in 24-h u5-HIAA at week 12. Patients (N = 76) were randomly assigned
(1:1:1) to receive placebo or telotristat ethyl 250 mg or 500 mg 3 times per
day (tid); 67 continued receiving telotristat ethyl 500 mg tid during the OLE.
Through week 12, TEAEs were generally mild to moderate in severity; 5
(placebo), 1 (telotristat ethyl 250 mg) and 3 (telotristat ethyl 500 mg)
patients experienced serious events, and the rate of TEAEs in the OLE was
comparable. At week 12, significant reductions in u5-HIAA from baseline were
observed, with Hodges–Lehmann estimators of median treatment differences from
placebo of −54.0% (95% confidence limits, −85.0%, −25.1%, P < 0.001) and
−89.7% (95% confidence limits, −113.1%, −63.9%, P < 0.001) for telotristat
ethyl 250 mg and 500 mg. These results support the safety and efficacy of
telotristat ethyl when added to SSAs in patients with CS diarrhea
(ClinicalTrials.gov identifier: Nbib2063659)
CXCL10 Can Inhibit Endothelial Cell Proliferation Independently of CXCR3
CXCL10 (or Interferon-inducible protein of 10 kDa, IP-10) is an interferon-inducible chemokine with potent chemotactic activity on activated effector T cells and other leukocytes expressing its high affinity G protein-coupled receptor CXCR3. CXCL10 is also active on other cell types, including endothelial cells and fibroblasts. The mechanisms through which CXCL10 mediates its effects on non-leukocytes is not fully understood. In this study, we focus on the anti-proliferative effect of CXCL10 on endothelial cells, and demonstrate that CXCL10 can inhibit endothelial cell proliferation in vitro independently of CXCR3. Four main findings support this conclusion. First, primary mouse endothelial cells isolated from CXCR3-deficient mice were inhibited by CXCL10 as efficiently as wildtype endothelial cells. We also note that the proposed alternative splice form CXCR3-B, which is thought to mediate CXCL10's angiostatic activity, does not exist in mice based on published mouse CXCR3 genomic sequences as an in-frame stop codon would terminate the proposed CXCR3-B splice variant in mice. Second, we demonstrate that human umbilical vein endothelial cells and human lung microvascular endothelial cells that were inhibited by CXL10 did not express CXCR3 by FACS analysis. Third, two different neutralizing CXCR3 antibodies did not inhibit the anti-proliferative effect of CXCL10. Finally, fourth, utilizing a panel of CXCL10 mutants, we show that the ability to inhibit endothelial cell proliferation correlates with CXCL10's glycosaminoglycan binding affinity and not with its CXCR3 binding and signaling. Thus, using a very defined system, we show that CXCL10 can inhibit endothelial cell proliferation through a CXCR3-independent mechanism
Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance
This white paper provides updated International Transporter Consortium (ITC) recommendations on transporters that are important in drug development following the 3rd ITC workshop. New additions include prospective evaluation of organic cation transporter 1 (OCT1) and retrospective evaluation of organic anion transporting polypeptide (OATP)2B1 because of their important roles in drug absorption, disposition, and effects. For the first time, the ITC underscores the importance of transporters involved in drug-induced vitamin deficiency (THTR2) and those involved in the disposition of biomarkers of organ function (OAT2 and bile acid transporters)
Can the Universe Create Itself?
The question of first-cause has troubled philosophers and cosmologists alike.
Now that it is apparent that our universe began in a Big Bang explosion, the
question of what happened before the Big Bang arises. Inflation seems like a
very promising answer, but as Borde and Vilenkin have shown, the inflationary
state preceding the Big Bang must have had a beginning also. Ultimately, the
difficult question seems to be how to make something out of nothing. This paper
explores the idea that this is the wrong question --- that that is not how the
Universe got here. Instead, we explore the idea of whether there is anything in
the laws of physics that would prevent the Universe from creating itself.
Because spacetimes can be curved and multiply connected, general relativity
allows for the possibility of closed timelike curves (CTCs). Thus, tracing
backwards in time through the original inflationary state we may eventually
encounter a region of CTCs giving no first-cause. This region of CTCs, may well
be over by now (being bounded toward the future by a Cauchy horizon). We
illustrate that such models --- with CTCs --- are not necessarily inconsistent
by demonstrating self-consistent vacuums for Misner space and a multiply
connected de Sitter space in which the renormalized energy-momentum tensor does
not diverge as one approaches the Cauchy horizon and solves Einstein's
equations. We show such a Universe can be classically stable and
self-consistent if and only if the potentials are retarded, giving a natural
explanation of the arrow of time. Some specific scenarios (out of many possible
ones) for this type of model are described. For example: an inflationary
universe gives rise to baby universes, one of which turns out to be itself.
Interestingly, the laws of physics may allow the Universe to be its own mother.Comment: 48 pages, 8 figure
INCITE: A randomised trial comparing constraint induced movement therapy and bimanual training in children with congenital hemiplegia
Background: Congenital hemiplegia is the most common form of cerebral palsy (CP) accounting for 1 in 1300 live births. These children have limitations in capacity to use the impaired upper limb and bimanual coordination deficits which impact on daily activities and participation in home, school and community life. There are currently two diverse intensive therapy approaches. Traditional therapy has adopted a bimanual approach (BIM training) and recently, constraint induced movement therapy (CIMT) has emerged as a promising unimanual approach. Uncertainty remains about the efficacy of these interventions and characteristics of best responders. This study aims to compare the efficacy of CIMT to BIM training to improve outcomes across the ICF for school children with congenital hemiplegia
Melioidosis Vaccines: A Systematic Review and Appraisal of the Potential to Exploit Biodefense Vaccines for Public Health Purposes
The designation of Burkholderia pseudomallei as a category B select agent has resulted in considerable research funding to develop a protective vaccine. This bacterium also causes a naturally occurring disease (melioidosis), an important cause of death in many countries including Thailand and Australia. In this study, we explored whether a vaccine could be used to provide protection from melioidosis. An economic evaluation based on its use in Thailand indicated that a vaccine could be a cost-effective intervention if used in high-risk populations such as diabetics and those with chronic kidney or lung disease. A literature search of vaccine studies in animal models identified the current candidates, but noted that models failed to take account of the common routes of infection in natural melioidosis and major risk factors for infection, primarily diabetes. This review highlights important areas for future research if biodefence-driven vaccines are to play a role in reducing the global incidence of melioidosis
Technology-assisted training of arm-hand skills in stroke: concepts on reacquisition of motor control and therapist guidelines for rehabilitation technology design
<p>Abstract</p> <p>Background</p> <p>It is the purpose of this article to identify and review criteria that rehabilitation technology should meet in order to offer arm-hand training to stroke patients, based on recent principles of motor learning.</p> <p>Methods</p> <p>A literature search was conducted in PubMed, MEDLINE, CINAHL, and EMBASE (1997–2007).</p> <p>Results</p> <p>One hundred and eighty seven scientific papers/book references were identified as being relevant. Rehabilitation approaches for upper limb training after stroke show to have shifted in the last decade from being analytical towards being focussed on environmentally contextual skill training (task-oriented training). Training programmes for enhancing motor skills use patient and goal-tailored exercise schedules and individual feedback on exercise performance. Therapist criteria for upper limb rehabilitation technology are suggested which are used to evaluate the strengths and weaknesses of a number of current technological systems.</p> <p>Conclusion</p> <p>This review shows that technology for supporting upper limb training after stroke needs to align with the evolution in rehabilitation training approaches of the last decade. A major challenge for related technological developments is to provide engaging patient-tailored task oriented arm-hand training in natural environments with patient-tailored feedback to support (re) learning of motor skills.</p
Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes
Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta-analysis. Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p = .0041). A meta-analysis (combing AD with NHL) implicated genes of apoptosis and telomere length. This GWAS-based analysis four NHL subtypes and three ADs revealed few weakly-associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs
ARDD 2020: from aging mechanisms to interventions
Aging is emerging as a druggable target with growing interest from academia, industry and investors. New technologies such as artificial intelligence and advanced screening techniques, as well as a strong influence from the industry sector may lead to novel discoveries to treat age-related diseases. The present review summarizes presentations from the 7th Annual Aging Research and Drug Discovery (ARDD) meeting, held online on the 1st to 4th of September 2020. The meeting covered topics related to new methodologies to study aging, knowledge about basic mechanisms of longevity, latest interventional strategies to target the aging process as well as discussions about the impact of aging research on society and economy. More than 2000 participants and 65 speakers joined the meeting and we already look forward to an even larger meeting next year. Please mark your calendars for the 8th ARDD meeting that is scheduled for the 31st of August to 3rd of September, 2021, at Columbia University, USA
Renewing cities, by Ross Gittell. Princeton, NJ: Princeton University Press, 1992, 232 pp., NPA
- …